Recent News

• 05.16.2025 - ATA Creativity Global Reports Q1 2025 Financial Results
• 05.14.2025 - ATA Creativity Global Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
• 05.09.2025 - ATA Creativity Global to Release 2025 First Quarter Financial Results on May 16
• 04.10.2025 - ATA Creativity Global Announces Filing of Annual Report on Form 20-F for the Year Ended December 31, 2024
• 03.25.2025 - ATA Creativity Global Reports Q4 and FY 2024 Financial Results
• 03.11.2025 - atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
• 03.05.2025 - atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
• 02.24.2025 - atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
• 02.24.2025 - Mark Scott
• 02.20.2025 - atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

Recent Filings

• 05.16.2025 - EX-99.1 EX-99.1
• 05.16.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.14.2025 - EX-99.1 EX-99.1
• 04.22.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 04.10.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.25.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]